CAPR vs IMSR Comparison

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Terrestrial Energy Inc develops Generation IV nuclear power plants based on its proprietary Integral Molten Salt Reactor (IMSR) technology. Its small modular reactor plants are designed to provide low-carbon electricity and high-temperature industrial heat for applications including power generation, petrochemical and chemical processing, and data centers. The company is working with regulators, suppliers, industrial partners, and energy users to develop, license, and commission IMSR plants.